## Abstract The high risk of recurrence in resected gastrointestinal stromal tumor (GIST) highlights the need for effective adjuvant treatment. This review evaluates the clinical efficacy and safety of imatinib for adjuvant treatment of localized KIT (CD117)βpositive resected GIST. Relevant studies
A systematic review on the clinical diagnosis of gastrointestinal stromal tumors
β Scribed by Marco Scarpa; Matteo Bertin; Cesare Ruffolo; Lino Polese; Davide F. D'Amico; Imerio Angriman
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 118 KB
- Volume
- 98
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Background and objective to analyze the frequency and spectrum of KIT and plateletβderived growth factor receptorβalpha (PDGFRA) gene in a large series of study and to explore the clinical implication of mutations in the gastrointestinal stromal tumors (GISTs) in China. ## Method
## Abstract ## BACKGROUND With the introduction of molecularly targeted therapy for gastrointestinal stromal tumors (GISTs), it became important to distinguish GISTs from leiomyosarcomas (LMSs). The authors sought to characterize the clinicopathologic features of these tumors in pediatric patients